



Annual Scientific Meeting 2023

Thursday 7 – Saturday 9 September 2023 • Manly Pacific Hotel, Sydney

Wednesday 6 September 2023.....	1
Thursday 7 September 2023.....	2
Friday 8 September 2023.....	3
Saturday 9 September 2023.....	4

Kindly note this is a working draft and speakers and session times are subject to change.

Wednesday 6 September 2023

2:00pm - 4:00pm	Career Planning Afternoon - Manly Surf Club <i>For Trainees/Fellows, Nurses, Allied Health Professionals</i>
4:00pm - 6:00pm	Delegate break
6:00pm - 9:00pm	ANZTCT Registry Planning Dinner (by invitation)

2023 Unrelated BMT Network Meeting

Hear an update from ABMDR on the current issues and challenges facing the sector, and our behind-the-scenes work to support patients and donors.

Click here to register for this free event
<https://www.eventbrite.com.au/e/abmdr-network-meeting-2023-tickets-672775207757>

Wednesday
6th September 2023
9:00AM - 4:30PM

Vibe Hotel Sydney
111 Goulburn St,
Sydney NSW 2000

<https://www.eventbrite.com.au/e/abmdr-network-meeting-2023-tickets-672775207757>

Thursday 7 September 2023

From 7:30am	Registration	
8:00am - 8:30am	Opening of ANZTCT ASM <i>Chairs: A/Prof Nada Hamad and Dr Duncan Purtill</i> <ul style="list-style-type: none"> ● Welcome to Country - Brendan Kerin ● Maori Address - Nadene Edmonds ● President's Address 	
Whole BMT Community Clinical Practice Session		
8:30am - 9:30am	GVHD at the extremes of age <i>Chairs: A/Prof Nada Hamad and Dr Duncan Purtill</i> <ul style="list-style-type: none"> ● Prof Paul Carpenter - Fred Hutchinson Cancer Centre 	
9:30am - 10:30am	PTCY in adults and paed: Why and how of PTCY <i>Chairs: A/Prof Nada Hamad and Dr Duncan Purtill</i> <ul style="list-style-type: none"> ● A/Prof Heather Symons - John Hopkins Children's Center 	
10:30am - 11:00am	Morning Tea - Sponsored by Ontime Couriers GmbH	
11:00am - 12:00pm	Plenary BMT Abstracts <i>Chairs: Dr Clinton Lewis and Yvonne Panek-Hudson</i> <ul style="list-style-type: none"> ● Min-Hi Han - Incidence, characteristics and organ involvement of chronic graft-versus-host disease measured by continuous National Institutes of Health consensus assessment ● Heather Dunckley - HLA-DPB1 protein expression in haematopoietic cell transplant patients in New Zealand ● Alia Cibich - Secondary malignancy after allogeneic haematopoietic stem cell transplant in adults: a single-centre registry analysis? 	
12:00pm - 1:30pm	Delegate Lunch	ANZTCT AGM (12:00pm - 12:40pm)
		Lunch 'n' Learn (12:50pm - 1:30pm) <i>Sponsored by Mallinckrodt Pharmaceuticals Chairs: Yvonne Panek-Hudson and Alex Rivalland</i> <i>Prof Paul Carpenter: The importance of diagnosing and managing GVHD early</i>
Showcasing Australian and New Zealand TCT Multidisciplinary Research and Science		
1:30pm - 2:00pm	Infection/Vaccination <i>Chairs: Dr Andrea Henden and A/Prof Emily Blyth</i> <ul style="list-style-type: none"> ● Dr Ben Teh - Peter MacCallum Cancer Centre 	
2:00pm - 2:30pm	Future of Microbiome in TCT <i>Chairs: Dr Andrea Henden and A/Prof Emily Blyth</i> <ul style="list-style-type: none"> ● Dr Craig Haifer - St Vincent's Hospital Sydney 	
2:30pm - 3:30pm	Oral Abstracts <i>Chairs: Dr Andrea Henden and A/Prof Emily Blyth</i> <ul style="list-style-type: none"> ● Phillip Selby - Optimising antifungal prophylaxis in allogeneic stem cell transplantation – a cohort study of two different approaches ● Phillip Selby - Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients ● Gaurav Sutrave - Third-party partially HLA matched fungus-specific T-cells can lead to clearance of invasive fungal infections in patients post-allogeneic bone marrow transplantation 	
3:30pm - 4:00pm	Afternoon Tea - Sponsored by Ontime Couriers GmbH	
4:00pm - 5:00pm	Oral Abstracts	

	<p><i>Chairs: Annette Trickett and John Coutsouvelis</i></p> <ul style="list-style-type: none"> • <i>Nienke Zomerdijk - Developing a psycho-educational resource for family stem cell donors</i> • <i>Julian Cooney - Optimising Bone Marrow Harvests: NMDP Mentorship & USA Centre of Excellence</i> • <i>Katie Jessen - Autologous stem cell mobilisation and transplant following bortezomib, lenalidomide and dexamethasone in multiple myeloma: single-centre experience</i> • <i>Aleece MacPhail - Post Allograft Immunoglobulin Replacement Study (PAIRS): protocol for an observational cohort study</i>
5:00pm - 6:00pm	Welcome Drinks - Fairy Bower Terrace

Partners

ANZTCT have partnered with the Australian Bone Marrow Donor Registry (ABMDR) and Arrow, the Bone Marrow Transplant Foundation to facilitate patient and caregiver education and engagement at this ASM.



ABMDR

The Australian Bone Marrow Donor Registry (ABMDR) is a not-for-profit organisation, and is the only Australian organisation responsible for arranging bone marrow/blood stem cell donations for patients in need of a transplant. ABMDR also administers government funding of public cord blood banks in Australia

<https://www.abmdr.org.au>

ARROW

Arrow, the Bone Marrow Foundation is dedicated to helping medical researchers find better treatments for diseases treatable by bone marrow transplants. Arrow fund HCC PhD scholarships to enable innovative bone marrow and stem cell research, provide opportunities for haematology nurses and help patients and carers with the cost of everyday living expenses.

<https://arrow.org.au>

Friday 8 September 2023

7:00am - 8:00am	Arrow Foundation Data Manager/QM Breakfast (by invitation)		
Registry data at the core of clinical quality and service planning			
8:00am - 8:40am	The importance and value of registry: CIBMTR perspectives <i>Chairs: Prof Peter Shaw and A/Prof Glen Kennedy</i> <ul style="list-style-type: none"> Prof Bronwen Shaw - Medical College of Wisconsin (supported by ABMDR) 		
8:40am - 9:00am	Value of (FACT/JACIE)Accreditation and improving patient outcomes <i>Chairs: Prof Peter Shaw and A/Prof Glen Kennedy</i> <ul style="list-style-type: none"> Dr Andrea Henden - Royal Brisbane Hospital 		
9:00am - 9:20am	Update on the Australian Commission on Safety and Quality in Health Care Clinical Quality Registry Program <i>Chairs: Prof Peter Shaw and A/Prof Glen Kennedy</i> <ul style="list-style-type: none"> Mr Suchit Handa - Program Director, Safety and Quality Improvement Systems 		
9:20am - 9:40am	Update from the Te Tāhū Hauora Health Quality & Safety Commission: Indigenous data Sovereignty <i>Chairs: Prof Peter Shaw and A/Prof Glen Kennedy</i> <ul style="list-style-type: none"> Peter Jansen - Chief Executive, NZ HQSC 		
9:40am - 10:10am	Morning Tea - Sponsored by Ontime Couriers GmbH		
10:10am - 10:30am	Registry update <i>Chairs: Prof Peter Shaw and A/Prof Glen Kennedy</i> <ul style="list-style-type: none"> Leonie Wilcox - ANZTCT Registry 		
10:30 - 11:30am	Panel Discussion: Future of Registry in TCT <i>Moderated by Prof Peter Shaw:</i> Panelists: <ul style="list-style-type: none"> Prof Bronwyn Shaw Suchit Handa Peter Jansen Leonie Wilcox A/Prof Glen Kennedy 		
11:30am - 12:00pm	Registry Research Proposals Announcement of ARROW scholarships for ANZTCT Registry disease specific outcomes projects <ul style="list-style-type: none"> <i>Chairs: Prof Jeff Szer and Richelle Koller</i> 		
12:00pm - 1:30pm	Delegate Lunch	Registry Stakeholder Networking Lunch <i>(ANZTCT/ABMDR/ARROW/LF/Commonwealth/Jurisdictions networking) by invitation</i>	Lunch 'n' Learn (from 1:00pm) <i>Sponsored by JazzPharma</i> <i>Chair: Dr Ian Bilmon</i> <i>John Coutsouvelis: VOD in ANZ and the new EBMT guidance and upcoming ANZTCT guidance</i>
Whole CART Community Clinical Practice Session			
1:30pm - 2:30pm	Neurotx management <i>Chairs: Prof Joy Ho and Kari Mudie</i> <ul style="list-style-type: none"> Prof Cameron Turtle - The University of Sydney 		
2:30pm - 3:30pm	CART debate - Is autograft in Lymphoma and Myeloma Dead? <i>Chairs: Prof Joy Ho and Kari Mudi</i> <ul style="list-style-type: none"> <i>Lymphoma: Dr Nausheen Ahmed (University of Kansas) Affirmative Vs Dr Ed Abadir (RPA Hospital) Negative</i> <i>Myeloma: Dr Nausheen Ahmed (University of Kansas) Affirmative Vs Dr Fiona Kwok (Westmead Hospital)</i> 		

	Negative
3:30pm - 4:00pm	Afternoon Tea - Sponsored by <i>Ontime Couriers GmbH</i>
4:00pm - 5:00pm	Plenary CT Abstracts <i>Chairs: Dr Rob Weinkove and Dr Duncan Purtil</i> <ul style="list-style-type: none"> - <i>Dr Ed Abadir: National CART Adult outcome Data</i> - <i>A/Prof Adam Nelson: National Paediatric outcome Data</i> - <i>Rebecca Wayte: Phenotyping CAR T-cells early post infusion reveals better clinical response rates for patients with high expression of PD1 on CD8 CAR T-cells</i> - <i>Dr Nausheen Ahmed: Real-world outcomes of brexucabtagene autoleucl (brexu-cel) for relapsed or refractory(R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment</i>
5:00pm - 6:00pm	Delegate break
6:30pm - 9:30pm	Family Dinner - Manly Skiff Club

Thank you to our Sponsors



Saturday 9 September 2023

From 7:30am	Registration	
Beyond the Cells: The future and sustainability of TCT		
8:00am - 8:20am	Donor sourcing - how that really works! <i>Chairs: Cushla Lucas and Carolyn Crump</i> <ul style="list-style-type: none"> • Lisa Smith - ABMDR 	
8:20am - 9:00am	How far can we mismatch to improve access to donors? <i>Chairs: Dr Myra Ruka and Carolyn Crump</i> <ul style="list-style-type: none"> • Prof Bronwen Shaw - Medical College of Wisconsin (supported by ABMDR) 	
9:00am - 10:00am	Access and Equity, Diversity and Inclusion in TCT <i>Chairs: Dr Nausheen Ahmed and Cushla Lucas</i> <ul style="list-style-type: none"> • Intersectionality in TCT: A/Prof Nada Hamad • Indigenous Perspective: Prof Maree Toombes • Indigenous Perspective: Dr Myra Ruka • Initiatives to support equity of access to CAR T cell therapies: Rob Weinkove 	
10:00am - 10:30am	What it takes to support TCT patients: Patient and family Perspectives <i>Chairs: A/Prof Adam Nelson and Dr Anna Johnston</i> Speakers: <ul style="list-style-type: none"> • Patient: Josh Polon • Parent: Hazel Polon 	
10:30am - 11:00am	Morning Tea - Sponsored by Ontime Couriers GmbH	
11:00am - 12:00pm	Panel: The future of TCT in ANZ: Policy design and strategic planning Workforce planning/Facilities/Health economics/Funding <i>Moderated by A/Prof Nada Hamad</i> Panelists: <ul style="list-style-type: none"> • Prof Bronwen Shaw - Medical College of Wisconsin (supported by ABMDR) • Peter Jansen - NZ HQSC • Paul Fennessy - Previously Department of Health Victoria • A/Prof Glen Kennedy - Royal Brisbane Hospital • Prof Maree Toombes - The University of Sydney • Annette Trickett - Cellular therapy scientist 	
12:00pm - 1:30pm	Delegate Lunch	Heads of TCT units Networking Lunch (by invitation)
Beyond the Cells: Survivorship (supported by ARROW) <i>Chairs: Dr Shahrukh Hashmi and Chris Murray</i>		
1:30pm - 1.50pm	Late BMT complications 1 <ul style="list-style-type: none"> • Megan Hogg - Westmead Hospital Sydney 	
1.50pm - 2:10pm	Late BMT complications 2 <ul style="list-style-type: none"> • Nicole Loft - SA Health 	
2:10pm - 2.30pm	Cognition in survivorship <ul style="list-style-type: none"> • Priscilla Gates - Deakin University 	
2.30pm - 2.50pm	Nutrition in CAR-T <ul style="list-style-type: none"> • Danika Carty - Peter MacCallum Cancer Centre 	
2.50pm - 3.10pm	Exercise in survivorship	

	<ul style="list-style-type: none"> • Dr Shaza Abo - Peter MacCallum Cancer Centre
3:10pm - 3:40pm	Afternoon Tea - Sponsored by <i>Ontime Couriers GmbH</i>
3.:40pm - 4:00pm	Graft versus Host Disease <ul style="list-style-type: none"> • Alex Rivalland - Royal Melbourne Hospital
4:00pm - 4.20pm	Vaccinations <ul style="list-style-type: none"> • Trish Joyce - Peter MacCallum Cancer Centre
4.20pm - 4.30pm	ANZTCT ASM Close

Reduce symptom burden with JAKAVI® (ruxolitinib) so they can get on with living^{1,2}

Clinically meaningful improvements* in symptoms and quality of life for Int-I patients with MF^{1,2}

*Patients achieving upper limit of the minimally important difference. FACT-Lym: 40.5%. FACIT: 47.0%²

FACIT, Functional Assessment of Chronic Illness Therapy; FACT-Lym, Functional Assessment of Cancer Therapy – Lymphoma Int-1, intermediate-1; MF, myelofibrosis

PBS Information: Graft vs Host Disease: Section 100 Highly Specialised Drugs Program Authority Required (Streamlined) for the treatment of patients with Grade II to IV acute graft vs host disease. Authority Required (Streamlined) for moderate to severe chronic graft vs host disease.
Myelofibrosis: Authority Required for high risk/intermediate-2 risk myelofibrosis and intermediate-1 risk myelofibrosis. Refer to the PBS Schedule for full Authority information.
Polycythaemia Vera - Not reimbursed.

FOR PRODUCT INFORMATION, [CLICK HERE](#).



This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.



References: 1. JAKAVI Approved Product Information. 2. Al-Ali HK *et al. Haematologica* 2016;101:1065–73. 3. Harrison CN *et al. Ann Hematol* 2017;96:1653–65. 4. Mesa RA *et al. Cancer* 2017;123:449–58. Novartis Pharmaceuticals Australia Pty Ltd, ABN 18 004 244 160, 54 Waterloo Road, Macquarie Park, NSW 2113. Ph (02) 9805 3555. For medical enquiries please contact 1800 671 203 (phone) or medinfo.phauno@novartis.com (email).
 ®Registered trademark. Item No: AU-20522/B. Date of preparation: March 2023. 2200881.

